VivoSim Labs Inc [VIVS] stock is trading at $2.09, up 3.97%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VIVS shares have gain 8.85% over the last week, with a monthly amount glided 5.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
VivoSim Labs Inc [NASDAQ: VIVS] stock has seen the most recent analyst activity on December 13, 2018, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $2.50. Previously, Raymond James downgraded its rating to Mkt Perform on November 10, 2017. On January 25, 2017, Raymond James initiated with a Outperform rating. Cantor Fitzgerald downgraded its rating to a Hold. Piper Jaffray initiated its recommendation with a Overweight and recommended $5 as its price target on June 29, 2015. Jefferies started tracking with a Buy rating for this stock on June 29, 2015, and assigned it a price target of $5.
VivoSim Labs Inc [VIVS] stock has fluctuated between $1.41 and $21.96 over the past year. VivoSim Labs Inc [NASDAQ: VIVS] shares were valued at $2.09 at the most recent close of the market.
Analyzing the VIVS fundamentals
VivoSim Labs Inc [NASDAQ:VIVS] reported sales of 0.14M for the trailing twelve months, which represents a drop of -6.67%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -86.94%, Pretax Profit Margin comes in at -14.15%, and Net Profit Margin reading is -14.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.29 and Total Capital is -1.68. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, VivoSim Labs Inc’s Current Ratio is 3.10. As well, the Quick Ratio is 3.10, while the Cash Ratio is 2.73. Considering the valuation of this stock, the price to sales ratio is 38.93, the price to book ratio is 0.77.
